New Study on Global Orphan Drugs Industry Key Trends, Size, Growth, Shares And Forecast (2017-2021)

Researchmoz added Most up-to-date research on "Global Orphan Drugs Market- Industry Analysis & Outlook (2017-2021)" to its huge collection of research reports.

An orphan disease refers to any rare disease which affects a smaller portion of population. Most of the rare diseases are genetic and therefore chronic. Presently, there are around 7000 rare diseases affecting approximately 5-6% of the global population. Half of the population of orphan disease patients is children as most of the genetic orphan diseases occur at birth or childhood.

Generally, orphan diseases are considered to be severe, progressive, degenerative, life-threatening or chronically debilitating diseases which can be caused genetically, infectiously or toxically. Despite knowing the causes of orphan diseases, most of these diseases are still non-curable or lack satisfactory treatments. Majority of the genetic orphan diseases are caused by defects in a single gene due to multiple mutations.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1217029

Orphan drug market is likely to witness a growth in future with the increasing development and approvals of ultra-rare drugs and rising developments in drugs for rare blood disease. The U.S. and Europe are the major contributors to the global orphan drugs market supported by increased numbers of orphan designations. Asia is likely to experience further growth with increasing drug approvals in Japan and improving healthcare facilities.

The global orphan drugs market is expected to grow in future due to prolonged orphan drug market exclusivity, increasing sales of prescription drugs, attractive orphan drug policies, rising healthcare expenditure, improving economies and increasing prevalence of chronic diseases. Key trends of this market include progressing drug pipeline, rising treatment options in oncology and rising scope in gene therapy. However, there are some factors which can hinder growth of the market including high costs of drugs, increased competition from generic industry, insufficient disease information & research participants and deficiency of diagnostic systems and trained professionals.

The report “Global Orphan Drugs Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S, Europe and Asia along with the global market. The report profiles key players of the market including Roche, Novartis, Bristol-Myers Squibb and Celgene.

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/global-orphan-drugs-market-industry-analysis-outlook-20172021-report.html/toc

Table of Content

1. Overview1.1 Orphan Disease
1.2 Orphan Drugs

2. Global Orphan Drugs Market
2.1 Orphan Drugs Market Value
2.2 Orphan Drugs Market Forecast by Value
2.3 Orphan Drugs Market by Product
2.4 Orphan Drugs Share in Prescription Drugs Market
2.5 Orphan Drugs Share Forecast in Prescription Drugs Market

3. Regional Markets
3.1 The Americas
3.1.1 The U.S Orphan Drugs Spending Forecast
3.1.2 The U.S. Orphan Drug Volume
3.1.3 The U.S. Orphan Drug Average & Median Cost per Patient
3.1.4 The U.S. Orphan Drug Average & Median Cost per Patient Forecast
3.1.5 Canada Orphan Drugs Spending
3.1.6 Canada Orphan Drugs Spending Forecast
3.2 Europe
3.2.1 Europe Orphan Drugs Market Forecast by Value
3.2.2 Europe Orphan Drugs Market by Product
3.2.3 Europe Orphan Drug Volume
3.3 Asia
3.3.1 Japan Orphan Drug Volume
3.3.2 India Orphan Drugs Market Value Forecast

4. Market Dynamics
.4.1 Growth Drivers
4.1.1 Prolonged Orphan Drug Market Exclusivity
4.1.2 Increasing Sales of Prescription Drugs
4.1.3 Attractive Orphan Drug Policies
4.1.4 Rising Healthcare Expenditure
4.1.5 Improving Economic Condition
4.1.6 Increasing Prevalence of Chronic Diseases
4.2 Key Trends
4.2.1 Progressing Drug Pipeline
4.2.2 Increasing Treatment Options in Oncology
4.2.3 Increasing Scope of Gene Therapy
4.3 Challenges
4.3.1 High Cost Drugs
4.3.2 Lack of Diagnostic Systems and Trained Professionals
4.3.3 Insufficient Disease Information and Research Participants
4.3.4 Rising Competition from Generic Industry

5. Competition
5.1 Global Market
5.1.1 Global Orphan Drugs Market Share by Company
5.2 Europe
5.2.1 Europe Orphan Drugs Market Share by Company

Continue...

Global Orphan Drugs Market- Industry Analysis & Outlook (2017-2021) Company Profiles – Roche, Novartis, Bristol-Myers Squibb, Celgene

Researchmoz added Most up-to-date research on "Global Orphan Drugs Market- Industry Analysis & Outlook (2017-2021)" to its huge collection of research reports.

An orphan disease refers to any rare disease which affects a smaller portion of population. Most of the rare diseases are genetic and therefore chronic. Presently, there are around 7000 rare diseases affecting approximately 5-6% of the global population. Half of the population of orphan disease patients is children as most of the genetic orphan diseases occur at birth or childhood.

Generally, orphan diseases are considered to be severe, progressive, degenerative, life-threatening or chronically debilitating diseases which can be caused genetically, infectiously or toxically. Despite knowing the causes of orphan diseases, most of these diseases are still non-curable or lack satisfactory treatments. Majority of the genetic orphan diseases are caused by defects in a single gene due to multiple mutations.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1217029

Orphan drug market is likely to witness a growth in future with the increasing development and approvals of ultra-rare drugs and rising developments in drugs for rare blood disease. The U.S. and Europe are the major contributors to the global orphan drugs market supported by increased numbers of orphan designations. Asia is likely to experience further growth with increasing drug approvals in Japan and improving healthcare facilities.

The global orphan drugs market is expected to grow in future due to prolonged orphan drug market exclusivity, increasing sales of prescription drugs, attractive orphan drug policies, rising healthcare expenditure, improving economies and increasing prevalence of chronic diseases. Key trends of this market include progressing drug pipeline, rising treatment options in oncology and rising scope in gene therapy. However, there are some factors which can hinder growth of the market including high costs of drugs, increased competition from generic industry, insufficient disease information & research participants and deficiency of diagnostic systems and trained professionals.

The report “Global Orphan Drugs Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S, Europe and Asia along with the global market. The report profiles key players of the market including Roche, Novartis, Bristol-Myers Squibb and Celgene.

Browse Detail Report With Full TOC @ https://www.researchmoz.us/global-orphan-drugs-market-industry-analysis-outlook-20172021-report.html

Table of Content

1. Overview1.1 Orphan Disease
1.2 Orphan Drugs

2. Global Orphan Drugs Market
2.1 Orphan Drugs Market Value
2.2 Orphan Drugs Market Forecast by Value
2.3 Orphan Drugs Market by Product
2.4 Orphan Drugs Share in Prescription Drugs Market
2.5 Orphan Drugs Share Forecast in Prescription Drugs Market

3. Regional Markets
3.1 The Americas
3.1.1 The U.S Orphan Drugs Spending Forecast
3.1.2 The U.S. Orphan Drug Volume
3.1.3 The U.S. Orphan Drug Average & Median Cost per Patient
3.1.4 The U.S. Orphan Drug Average & Median Cost per Patient Forecast
3.1.5 Canada Orphan Drugs Spending
3.1.6 Canada Orphan Drugs Spending Forecast
3.2 Europe
3.2.1 Europe Orphan Drugs Market Forecast by Value
3.2.2 Europe Orphan Drugs Market by Product
3.2.3 Europe Orphan Drug Volume
3.3 Asia
3.3.1 Japan Orphan Drug Volume
3.3.2 India Orphan Drugs Market Value Forecast

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Prolonged Orphan Drug Market Exclusivity
4.1.2 Increasing Sales of Prescription Drugs
4.1.3 Attractive Orphan Drug Policies
4.1.4 Rising Healthcare Expenditure
4.1.5 Improving Economic Condition
4.1.6 Increasing Prevalence of Chronic Diseases
4.2 Key Trends
4.2.1 Progressing Drug Pipeline
4.2.2 Increasing Treatment Options in Oncology
4.2.3 Increasing Scope of Gene Therapy
4.3 Challenges
4.3.1 High Cost Drugs
4.3.2 Lack of Diagnostic Systems and Trained Professionals
4.3.3 Insufficient Disease Information and Research Participants
4.3.4 Rising Competition from Generic Industry

5. Competition
5.1 Global Market
5.1.1 Global Orphan Drugs Market Share by Company
5.2 Europe
5.2.1 Europe Orphan Drugs Market Share by Company

6. Company Profiles
6.1 Roche
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Novartis
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Bristol-Myers Squibb
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Celgene
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies

Make an Enquiry of this report @ https://www.researchmoz.us/enquiry.php?type=E&repid=1217029

Global Orphan Drugs Market To Grow At A CAGR Of 10.20% During The Period 2017-2021 Key vendors – AbbVie, Celgene, F. Hoffmann La Roche, Novartis

Researchmoz added Most up-to-date research on "Global Orphan Drugs Market 2017-2021" to its huge collection of research reports.

According to Orphan Drug Designation program of the US Food and Drug Administration (FDA), orphan diseases are defined as rare diseases that affects less than 2,00,000 Americans. The global orphan drugs market is expected to benefit from patent extensions like Orphan Drug Exclusivity (ODE), increasing focus of vendors on orphan drug products, and financial incentives provided by government in form of tax credits and waived FDA fees. For instance, the FDA grants a seven-year patent exclusivity to orphan drugs to treat a rare disease. Therefore, any other drug with the same indication cannot be approved by the FDA during these seven-years period. In addition, they also provide tax credits up to 50% of the total R&D cost after the drug receives the orphan drug designation. This credit can be used by the sponsor during the R&D phase of any drug irrespective of the drug designation. The orphan designated drugs are also exempted from paying the FDA fees. Thus, these financial incentives and grants for orphan drug attract many vendors to invest in developing drugs for rare diseases and make huge profits.

Technavios analysts forecast the global orphan drugs market to grow at a CAGR of 10.20% during the period 2017-2021.


To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1059719

Covered in this report
The report covers the present scenario and the growth prospects of the global orphan drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Global Orphan Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
AbbVie
Celgene
F. Hoffmann La Roche
Novartis

Browse Detail Report With Full TOC @ https://www.researchmoz.us/global-orphan-drugs-market-2017-2021-report.html

Other prominent vendors
Amgen
Actelion
Alexion Pharmaceuticals
Bayer
Biogen
Bristol-Myers Squibb
Eli Lilly
Johnson & Johnson
Novo Nordisk
Pfizer
Sanofi
Shire
Teva pharmaceutical

Market driver
Large growth opportunities through orphan drug designation.
For a full, detailed list, view our report

Market challenge
Costly treatment regimen results in financial burden on patients.
For a full, detailed list, view our report

Market trend
Emerging application for orphan drug development.
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1059719

Global Orphan Drugs Industry Key Trends, Size, Growth, Shares And Forecast Research Report 2016

Researchmoz added Most up-to-date research on "Global Orphan Drugs Market Report: 2016 Edition" to its huge collection of research reports.

A rare disease is the one that occurs uncommonly or rarely in the general population.

However, there exists no clear definition for categorizing “rare diseases” and is usually defined on the basis of the prevalence, and some other factors including the severity of disease and availability of treatment options. Rare diseases are often serious, chronic and progressive. Orphan drugs are medicinal products intended for the diagnosis, prevention or treatment of rare diseases. These drugs are referred to be “orphan” as under normal conditions because these drugs are not cost effective to be developed by the pharmaceuticals industry, intended for a small number of patients suffering from rare conditions.

Increasing sales of prescription drugs, substantial benefits for new entrants in rare disease drug market, increased spending on medicines, rising healthcare expenditure and improving economic conditions of nations are some of the significant factors driving growth of the Orphan drugs market. However, the growth of the market is hindered by certain challenges including tougher regulatory approvals, limitation on charging higher prices and no approved drugs for several rare diseases including Polychethemia Vera (PV).

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=548106

The global orphan drugs market is expected to see numerous developments including approval of several Ultra-Rare drugs, increasing scope of Gene therapy, development of drugs for rare blood disease, higher success prospects for Hematology compared to Solid Tumors, attractive pricing option for orphan drug competitors and striking opportunities in developing orphan drugs.

The report, “Global Orphan Drugs Market” analyzes the current prevailing condition of the market along with its future scope of development. The global market along with specific market of the U.S., Canada, Europe and Japan, is being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.

Table of Content

1. Orphan Diseases: Introduction1.1 Causes   
1.2 Prevention   
1.3 Diagnosis   
1.4 Treatment Options   
1.5 Orphan Drugs

2. Market Analysis
2.1 Global Orphan Drugs Market

    Market Value
    Growth Rate
    Market Segmentation

2.1.1 NonHodgkin’s Lymphoma (NHL) Market

3. Regional Analysis
3.1 The U.S. Orphan Drugs Market

    Applications & Designations
    Spending Growth Forecast

3.1.1 The UltraRare Drugs Market
3.2 Canada   
3.3 Europe   
3.4 Japan

4. Market Dynamics
4.1 Key Trends and Developments
4.1.1 Striking Opportunities in Developing Orphan Drugs
4.1.2 Attractive Pricing Option for Orphan Drug Companies   
4.1.3 Higher Success Prospect for Hematology vs. Solid Tumors   
4.1.4 Development of Drugs for Rare Blood Diseases   
4.1.5 Increasing Scope of Gene Therapy   
4.1.6 Approval of UltraOrphan Drugs
4.2 Growth Drivers
4.2.1 Increasing Sales of Prescription Drugs   
4.2.2 Substantial Benefits for New Entrants in Rare Diseases Market   
4.2.3 Increased Spending on Medicines   
4.2.4 Rising Healthcare Expenditure   
4.2.5 Rising Global GDP
4.3 Challenges
4.3.1 Limitation on Charging High Price for Orphan Drugs   
4.3.2 No Approved Drug for Polycythemia Vera Firstline Treatment   
4.3.3 Tough Regulatory Approval for Orphan Drugs

5. Competitive Landscape
5.1 Global Market

    Market Share
    Product Comparison

5.2 The U.S. Market

    Market Share
    Product Comparison

6. Company Profiles
6.1 Roche Holdings
6.1.1 Business Overview   
6.1.2 Financial Overview   
6.1.3 Business Strategies
6.2 Novartis
6.2.1 Business Overview   
6.2.2 Financial Overview   
6.2.3 Business Strategies
6.3 Celgene Corporation
6.3.1 Business Overview   
6.3.2 Financial Overview   
6.3.3 Business Strategies
6.4 Novo Nordisk
6.4.1 Business Overview   
6.4.2 Financial Overview   
6.4.3 Business Strategies
6.5 Eli Lilly and Company
6.5.1 Business Overview   
6.5.2 Financial Overview   
6.5.3 Business Strategies

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=548106

Global Orphan Drugs Market To Grow At A CAGR Of 10.20% During The Period 2017-2021

Researchmoz added Most up-to-date research on "Global Orphan Drugs Market 2017-2021" to its huge collection of research reports.

According to Orphan Drug Designation program of the US Food and Drug Administration (FDA), orphan diseases are defined as rare diseases that affects less than 2,00,000 Americans. The global orphan drugs market is expected to benefit from patent extensions like Orphan Drug Exclusivity (ODE), increasing focus of vendors on orphan drug products, and financial incentives provided by government in form of tax credits and waived FDA fees. For instance, the FDA grants a seven-year patent exclusivity to orphan drugs to treat a rare disease. Therefore, any other drug with the same indication cannot be approved by the FDA during these seven-years period. In addition, they also provide tax credits up to 50% of the total R&D cost after the drug receives the orphan drug designation. This credit can be used by the sponsor during the R&D phase of any drug irrespective of the drug designation. The orphan designated drugs are also exempted from paying the FDA fees. Thus, these financial incentives and grants for orphan drug attract many vendors to invest in developing drugs for rare diseases and make huge profits.

Technavios analysts forecast the global orphan drugs market to grow at a CAGR of 10.20% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global orphan drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1059719

Technavio's report, Global Orphan Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
AbbVie
Celgene
F. Hoffmann La Roche
Novartis

Other prominent vendors
Amgen
Actelion
Alexion Pharmaceuticals
Bayer
Biogen
Bristol-Myers Squibb
Eli Lilly
Johnson & Johnson
Novo Nordisk
Pfizer
Sanofi
Shire
Teva pharmaceutical

Market driver
Large growth opportunities through orphan drug designation.
For a full, detailed list, view our report

Market challenge
Costly treatment regimen results in financial burden on patients.
For a full, detailed list, view our report

Market trend
Emerging application for orphan drug development.
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1059719